glp 1 drug novo nordisk Hair loss with GLP-1 drugs is rare, but real, studies find Novo asks FDA to prevent

10.1056/NEJMra2026131 N Engl J Med

The primary outcome was the incidence of overall thyroid disorders, and the secondary outcomes included the incidence of goiter, hyperthyroidism, hypothyroidism, thyroiditis, thyroid mass, and thyroid cancer

Consistently, in the present study lower C2 levels as compared to healthy controls were observed for subjects experiencing a current depressive episode as well those who had remitted

These activities are designed to meet the unique sensory needs of individuals with autism

with VIP (Vasoactive Intestinal Peptide), which has potent anti-inflammatory, neuroprotective, and immune-modulating effects